Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
August 14, 2024 16:05 ET | Cyclacel
Cyclacel provides Q2 2024 financial results and business update on fadraciclib precision medicine strategy
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
August 07, 2024 09:15 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology
November 01, 2012 07:00 ET | Cyclacel Pharmaceuticals, Inc.
Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AML Updated Survival Data From a Pilot Study and Lead-In Phase of...